VolitionRX Ltd (NYSEAMERICAN:VNRX) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 327,999 shares, an increase of 80.3% from the December 14th total of 181,885 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily trading volume, of 113,840 shares, the short-interest ratio is currently 2.9 days.

An institutional investor recently raised its position in VolitionRX stock. Bridgeway Capital Management Inc. raised its stake in VolitionRX Ltd (NYSEAMERICAN:VNRX) by 12.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 224,400 shares of the medical research company’s stock after buying an additional 25,000 shares during the period. Bridgeway Capital Management Inc. owned about 0.64% of VolitionRX worth $581,000 at the end of the most recent quarter.

Separately, Oppenheimer set a $5.00 target price on shares of VolitionRX and gave the company a “buy” rating in a research note on Friday, November 9th.

NYSEAMERICAN VNRX opened at $2.33 on Friday. VolitionRX has a fifty-two week low of $1.44 and a fifty-two week high of $4.00.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings data on Wednesday, November 7th. The medical research company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14).

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2019/01/11/volitionrx-ltd-vnrx-short-interest-up-80-3-in-december.html.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Featured Article: What is Cost of Capital?

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.